SG Americas Securities LLC Sells 8,815 Shares of TransMedics Group, Inc. $TMDX

SG Americas Securities LLC lowered its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 56.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 6,910 shares of the company’s stock after selling 8,815 shares during the quarter. SG Americas Securities LLC’s holdings in TransMedics Group were worth $687,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd purchased a new stake in TransMedics Group during the 3rd quarter valued at $29,000. Allworth Financial LP raised its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of TransMedics Group during the third quarter valued at approximately $34,000. Finally, Hantz Financial Services Inc. grew its stake in TransMedics Group by 196.2% in the fourth quarter. Hantz Financial Services Inc. now owns 311 shares of the company’s stock worth $38,000 after purchasing an additional 206 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Performance

TMDX traded down $0.73 during mid-day trading on Tuesday, reaching $70.50. 27,762 shares of the company traded hands, compared to its average volume of 1,102,058. The company’s fifty day moving average price is $74.20 and its 200-day moving average price is $107.75. The stock has a market capitalization of $2.44 billion, a P/E ratio of 16.03 and a beta of 1.89. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue was up 21.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 EPS. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1.92 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on TMDX. UBS Group reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Needham & Company LLC cut their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Piper Sandler cut their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and a consensus target price of $134.50.

Insider Activity

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.